NasdaqGS:DFTXPharmaceuticals
Does Definium Therapeutics' (DFTX) New Phase 3 Trial Clarify Its Psychedelic Depression Strategy Or Cloud It?
Earlier in May 2026, Definium Therapeutics dosed the first patient in Ascend, its second Phase 3 trial of DT120 ODT for major depressive disorder, a 175-participant U.S. study using MADRS score change at Week 6 as the primary endpoint.
This trial extends Definium’s effort to build a broad DT120 ODT franchise across depression, anxiety, and PTSD using a proprietary LSD-based, fast-dissolve formulation aligned with prior Phase 2b data and FDA guidance.
We’ll now examine how initiating the...